Selective enhancement by cyclosporin A of collagen expression by mesangial cells 'in culture'

Gian Marco Ghiggeri, Paola Altieri, Roberta Oleggini, Franca Spada, Fabrizio Ginevri, Francesco Perfumo, Rosanna Gusmano

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Extracellular matrix deposition in mesangial areas leading to glomerulosclerosis is the major side effect of protracted therapies with cyclosporin A. In order to define any direct correlation between a chronic therapy with the drug and glomerulosclerosis we studied the effects of cyclosporin A on extracellular matrix production by human mesangial cells in culture. By immunoprecipitation and sodium dodecyl sulfate polyacrylamide electrophoresis (SDS-PAGE) of [3H]proline-labeled mesangial cells it was found that cyclosporin A induced a dose-dependent increase in total collagen synthesis (+80%), corresponding to a net increment in collagen III (+120%) and in a component with 70 kDa molecular weight which was produced only in negligible amount by mesangial cells under standard conditions. This collagen was characterized by cyanogen bromide digestion and finger print analysis as a novel molecule, not sharing any peptide composition similarities with the already characterized collagens. These data indicate that cyclosporin A stimulates the synthesis by mesangial cells of selected collagens, mainly collagen III and a new low molecular weight component. This mechanism may be relevant in cyclosporin A induced glomerulosclerosis occuring during protracted therapies with the drug.

Original languageEnglish
Pages (from-to)195-201
Number of pages7
JournalEuropean Journal of Pharmacology: Environmental Toxicology and
Volume270
Issue number2-3
DOIs
Publication statusPublished - Apr 4 1994

Fingerprint

Mesangial Cells
Collagen
Cyclosporine
Cell Culture Techniques
Extracellular Matrix
Molecular Weight
Molecular weight
Drug Therapy
Cyanogen Bromide
Sodium dodecyl sulfate
Polyacrylates
Electrophoresis
Immunoprecipitation
Proline
Sodium Dodecyl Sulfate
Pharmaceutical Preparations
Peptides
Fingers
Polyacrylamide Gel Electrophoresis
Digestion

Keywords

  • Cyclosporin A
  • Extracellular matrix
  • Glomerulosclerosis
  • Mesangial cell

ASJC Scopus subject areas

  • Pollution
  • Pharmacology
  • Toxicology

Cite this

Selective enhancement by cyclosporin A of collagen expression by mesangial cells 'in culture'. / Ghiggeri, Gian Marco; Altieri, Paola; Oleggini, Roberta; Spada, Franca; Ginevri, Fabrizio; Perfumo, Francesco; Gusmano, Rosanna.

In: European Journal of Pharmacology: Environmental Toxicology and, Vol. 270, No. 2-3, 04.04.1994, p. 195-201.

Research output: Contribution to journalArticle

Ghiggeri, Gian Marco ; Altieri, Paola ; Oleggini, Roberta ; Spada, Franca ; Ginevri, Fabrizio ; Perfumo, Francesco ; Gusmano, Rosanna. / Selective enhancement by cyclosporin A of collagen expression by mesangial cells 'in culture'. In: European Journal of Pharmacology: Environmental Toxicology and. 1994 ; Vol. 270, No. 2-3. pp. 195-201.
@article{836da06de19248b8a8bb0a178a28042d,
title = "Selective enhancement by cyclosporin A of collagen expression by mesangial cells 'in culture'",
abstract = "Extracellular matrix deposition in mesangial areas leading to glomerulosclerosis is the major side effect of protracted therapies with cyclosporin A. In order to define any direct correlation between a chronic therapy with the drug and glomerulosclerosis we studied the effects of cyclosporin A on extracellular matrix production by human mesangial cells in culture. By immunoprecipitation and sodium dodecyl sulfate polyacrylamide electrophoresis (SDS-PAGE) of [3H]proline-labeled mesangial cells it was found that cyclosporin A induced a dose-dependent increase in total collagen synthesis (+80{\%}), corresponding to a net increment in collagen III (+120{\%}) and in a component with 70 kDa molecular weight which was produced only in negligible amount by mesangial cells under standard conditions. This collagen was characterized by cyanogen bromide digestion and finger print analysis as a novel molecule, not sharing any peptide composition similarities with the already characterized collagens. These data indicate that cyclosporin A stimulates the synthesis by mesangial cells of selected collagens, mainly collagen III and a new low molecular weight component. This mechanism may be relevant in cyclosporin A induced glomerulosclerosis occuring during protracted therapies with the drug.",
keywords = "Cyclosporin A, Extracellular matrix, Glomerulosclerosis, Mesangial cell",
author = "Ghiggeri, {Gian Marco} and Paola Altieri and Roberta Oleggini and Franca Spada and Fabrizio Ginevri and Francesco Perfumo and Rosanna Gusmano",
year = "1994",
month = "4",
day = "4",
doi = "10.1016/0926-6917(94)90063-9",
language = "English",
volume = "270",
pages = "195--201",
journal = "European Journal of Pharmacology - Environmental Toxicology and Pharmacology Section",
issn = "0926-6917",
publisher = "Elsevier BV",
number = "2-3",

}

TY - JOUR

T1 - Selective enhancement by cyclosporin A of collagen expression by mesangial cells 'in culture'

AU - Ghiggeri, Gian Marco

AU - Altieri, Paola

AU - Oleggini, Roberta

AU - Spada, Franca

AU - Ginevri, Fabrizio

AU - Perfumo, Francesco

AU - Gusmano, Rosanna

PY - 1994/4/4

Y1 - 1994/4/4

N2 - Extracellular matrix deposition in mesangial areas leading to glomerulosclerosis is the major side effect of protracted therapies with cyclosporin A. In order to define any direct correlation between a chronic therapy with the drug and glomerulosclerosis we studied the effects of cyclosporin A on extracellular matrix production by human mesangial cells in culture. By immunoprecipitation and sodium dodecyl sulfate polyacrylamide electrophoresis (SDS-PAGE) of [3H]proline-labeled mesangial cells it was found that cyclosporin A induced a dose-dependent increase in total collagen synthesis (+80%), corresponding to a net increment in collagen III (+120%) and in a component with 70 kDa molecular weight which was produced only in negligible amount by mesangial cells under standard conditions. This collagen was characterized by cyanogen bromide digestion and finger print analysis as a novel molecule, not sharing any peptide composition similarities with the already characterized collagens. These data indicate that cyclosporin A stimulates the synthesis by mesangial cells of selected collagens, mainly collagen III and a new low molecular weight component. This mechanism may be relevant in cyclosporin A induced glomerulosclerosis occuring during protracted therapies with the drug.

AB - Extracellular matrix deposition in mesangial areas leading to glomerulosclerosis is the major side effect of protracted therapies with cyclosporin A. In order to define any direct correlation between a chronic therapy with the drug and glomerulosclerosis we studied the effects of cyclosporin A on extracellular matrix production by human mesangial cells in culture. By immunoprecipitation and sodium dodecyl sulfate polyacrylamide electrophoresis (SDS-PAGE) of [3H]proline-labeled mesangial cells it was found that cyclosporin A induced a dose-dependent increase in total collagen synthesis (+80%), corresponding to a net increment in collagen III (+120%) and in a component with 70 kDa molecular weight which was produced only in negligible amount by mesangial cells under standard conditions. This collagen was characterized by cyanogen bromide digestion and finger print analysis as a novel molecule, not sharing any peptide composition similarities with the already characterized collagens. These data indicate that cyclosporin A stimulates the synthesis by mesangial cells of selected collagens, mainly collagen III and a new low molecular weight component. This mechanism may be relevant in cyclosporin A induced glomerulosclerosis occuring during protracted therapies with the drug.

KW - Cyclosporin A

KW - Extracellular matrix

KW - Glomerulosclerosis

KW - Mesangial cell

UR - http://www.scopus.com/inward/record.url?scp=0028344940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028344940&partnerID=8YFLogxK

U2 - 10.1016/0926-6917(94)90063-9

DO - 10.1016/0926-6917(94)90063-9

M3 - Article

C2 - 8039549

AN - SCOPUS:0028344940

VL - 270

SP - 195

EP - 201

JO - European Journal of Pharmacology - Environmental Toxicology and Pharmacology Section

JF - European Journal of Pharmacology - Environmental Toxicology and Pharmacology Section

SN - 0926-6917

IS - 2-3

ER -